The (patho)physiological roles of PPARδ are understood less, perhaps because the PPARδ-selective agonists were not available clinically until the accelerated approval of seladelpar on 8/14/2024 for the treatment of primary biliary cholangitis [6]. Here, PPARD is linked to biliary liver cirrhosis.